title: Immunoregulatory effects of interleukin 2 and interferon on syngeneic murine malignant glioma-specific cytotoxic T-lymphocytes.
abstract: The effects of interleukin 2 (IL2) and interferon (IFN) on the generation and lytic activation of syngeneic murine malignant glioma (a methylcholanthrene-induced ependymoblastoma of C57BL/6 mouse origin, 203-glioma)-specific cytotoxic T-lymphocyte (G-CTL) were investigated. The surface marker analysis showed that G-CTLs from both intracranial and s.c. tumor-bearing mice were composed of thymectomy-resistant (mature) Lyt-1-.2.3+ and thymectomy-sensitive (immature) Lyt-1+.2.3+ CTLs, which markedly decreased concurrently with increased intracranial pressure. G-CTLs were confirmed to be activated with target specificity by both factors in a different way. The CTL activation by IL2 (20 units/ml) remained for a longer time, although a lag time of 5 days after initial culture was required. IL2 influenced Lyt-1+.2.3+ CTLs to proliferate and develop the lytic potential. In contrast, even a 3-h incubation with IFN (1000 units/ml) could enhance the cytotoxicity, but the augmenting effects were observed no longer than 5 days later. IFN activated Lyt-1-.2.3+ CTLs and increased their proportion of the total cell population with a simultaneous decrease of Lyt-1+.2.3+ CTLs. Therefore, it was suggested that IL2 may provide a growth of CTL populations and that IFN can accelerate recruitment of new effectors, causing activation of the lytic process.
authors.affiliation: Department of Neurosurgery, Medical School, Kyoto University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yamasaki
authors.forename: H
authors.initials: H
authors.lastname: Kikuchi
authors.forename: J
authors.initials: J
authors.lastname: Yamashita
authors.forename: H
authors.initials: H
authors.lastname: Handa
authors.forename: S
authors.initials: S
authors.lastname: Kuwata
authors.forename: M
authors.initials: M
authors.lastname: Taguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Namba
authors.forename: M
authors.initials: M
authors.lastname: Hanaoka
mesh_terms: D000818:Animals; D003165:Complement System Proteins / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D005910:Glioma / Q000276:immunology*; D007370:Interferon Type I / Q000276:immunology*; D007376:Interleukin-2 / Q000276:immunology* / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology; D051381:Rats; D011919:Rats, Inbred Strains; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D007370:Interferon Type I; D007376:Interleukin-2; D003165:Complement System Proteins